Overview

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Status:
Not yet recruiting
Trial end date:
2029-01-08
Target enrollment:
Participant gender:
Summary
The purpose is to provide treatment with secukinumab delivered subcutaneously (s.c.) via pre-filled syringe (PFS) for participants who complete study treatment until the Week 104 of the core study CAIN457Q12301 and to obtain long term efficacy, safety and tolerability data
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals